Tübingen, Germany

Janet Peper

This inventor holds 26 USPTO granted patents and 10 published patent applications and 1 EPO patent, primarily in Immunotherapy Research. Top assignee: Immatics Biotechnologies Gmbh. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Janet Peper. Retrieved from https://idiyas.com/inventor/janet-peper

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 80.8

 

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 116(Granted Patents)


Location History:

  • Tuebingen, DE (2018 - 2024)
  • Freising, DE (2020 - 2024)

Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Peptides
Immunotherapy
Ovarian Cancer
Cancer Treatment
Combination Therapy
Epithelial Cancer
Therapeutic Applications
Oncology Research
Cancer Immunology
Biotechnology
Cancer Therapies
Targeted Therapy
26 patents (USPTO):Explore Patents

Title: **The Innovative Contributions of Janet Peper in Immunotherapy**

Introduction

Janet Peper is a prominent inventor based in Tuebingen, Germany, known for her significant contributions to immunotherapy, particularly in the field of cancer treatment. With a remarkable portfolio of 26 patents, her work is at the forefront of scientific innovation, making strides in how we approach cancer therapies.

Latest Patents

One of Janet Peper's latest patents focuses on "Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers." This invention encompasses peptides, proteins, nucleic acids, and cells intended for immunotherapeutic methods. It specifically pertains to cancer immunotherapy, highlighting tumor-associated T-cell peptide epitopes, which can serve as active pharmaceutical ingredients in vaccine compositions aimed at stimulating anti-tumor immune responses. Moreover, these peptides may aid in the stimulation of T cells ex vivo and their subsequent transfer to patients. Additionally, her patents discussed the potential of peptides bound to molecules of the major histocompatibility complex (MHC), identifying them as targets for antibodies, soluble T-cell receptors, and other binding molecules.

Career Highlights

Janet Peper has established herself as an expert in her field while working at Immatics Biotechnologies GmbH. Her career has been marked by a dedication to advancing cancer treatments through innovative research and the development of novel therapeutic methods. Her extensive experience in the biotechnology sector has equipped her with unique insights into the challenges of cancer immunotherapy.

Collaborations

Throughout her career, Janet has collaborated with distinguished colleagues, including Heiko Schuster and Hans-Georg Rammensee. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the collective pursuit of groundbreaking discoveries in cancer research.

Conclusion

Janet Peper's work and patents significantly impact the field of immunotherapy, driving forward the development of new treatments for cancer. As research continues to evolve, her contributions will undoubtedly play a vital role in shaping the future of cancer care and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…